Mattia Congia

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 315 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Felice Rivellese, Anna E. A. Surace, Katriona Goldmann et al. · Nature Medicine · 2022 · 279 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus

Matteo Piga, Alberto Floris, Giulia Cappellazzo et al. · Arthritis Research & Therapy · 2017 · 95 citations · Full text

Life Sciences, Clinical Sciences, Internal Medicine +15

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

Felice Rivellese, Alessandra Nerviani, Giovanni Giorli et al. · The Lancet Rheumatology · 2023 · 68 citations · Full text

Medicine, Immunology, Pathobiology +15

Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus

Matteo Piga, Mattia Congia, Alessandra Gabba et al. · Lupus · 2017 · 54 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17